olaparib

DNA helix forming inside a test tube
Research

PARP combo shows promise in ovarian and breast cancer models

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.
Arlene Weintraub Oct 24, 2020 4:00am
glioblastoma

Could AstraZeneca’s ovarian cancer drug also treat glioblastoma?

Nov 6, 2017 8:39am
ovarian

Moving PARP inhibitors beyond BRCA cancers

Jul 26, 2017 3:14pm
Boston

Medivation’s VP of clinical development jumps ship to rival PARP biotech

Aug 25, 2016 6:09am
AstraZeneca London HQ

UPDATED: Q2 clear-out sees AstraZeneca dump gastric cancer, NASH PhIII studies

Jul 28, 2016 4:17am